TOKYO & SANTA CLARA, Calif.--(BUSINESS WIRE)--Astellas Pharma Inc. (Astellas) and XenoPort, Inc. (NASDAQ:XNPT) today announced preliminary top-line results from a Phase 2 clinical trial of ASP8825/XP13512 for the treatment of symptoms in moderate-to-severe primary restless legs syndrome (RLS) patients. The trial was conducted by Astellas in Japan. ASP8825/XP13512 demonstrated statistically significant improvements compared to placebo on the primary endpoint of the trial and was well tolerated.
